ArticleJournal of Alzheimer's disease : JAD2017
PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.
Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration.Diagnostics (Basel, Switzerland) · 2024Guideline
- Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease.Alzheimer's research & therapy · 2023Pooled it
- Mapping Knowledge Landscapes and Emerging Trends in AI for Dementia Biomarkers: Bibliometric and Visualization Analysis.Journal of medical Internet research · 2024Article
- Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology.Nature communications · 2024Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Prevention of Alzheimer's disease through diet: An exploratory review.Metabolism open · 2023Review
- Serum brain-derived neurotrophic factor levels as a predictor for Alzheimer disease progression.Journal of the Chinese Medical Association : JCMA · 2023Observational
- Utility of the Comprehensive Trail Making Test in the Assessment of Mild Cognitive Impairment in Older Patients.Geriatrics (Basel, Switzerland) · 2023Article
- Tau: a biomarker of Huntington's disease.Molecular psychiatry · 2023Review
- Role of the amygdala-medial orbitofrontal relationship in odor recognition in the elderly.Brain and behavior · 2023Article
- Biomarkers for dementia in Latin American countries: Gaps and opportunities.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Untangling the Role of Tau in Huntington's Disease Pathology.Journal of Huntington's disease · 2023Review
- Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.Brain : a journal of neurology · 2022Article
- A Machine Learning-Based Approach to Discrimination of Tauopathies Using [Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease.Journal of neurology · 2022Article
- Patterns of tau pathology identified withAlzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Neurons derived from individual early Alzheimer's disease patients reflect their clinical vulnerability.Brain communications · 2022Article
- Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease.Frontiers in aging neuroscience · 2022Article
- Cascade process mediated by left hippocampus and left superior frontal gyrus affects relationship between aging and cognitive dysfunction.BMC neuroscience · 2021Article
- Clinical validity of increased cortical uptake of [European journal of nuclear medicine and molecular imaging · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundCombining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD).
objectiveWe sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology.
methodsWe conducted a multi-center observational study in early AD (MMSE >20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of Aβ and tau at baseline and 6 months; PET-CT imaging with Aβ ([18F]AV45) and tau ([18F]AV1451) ligands at baseline.
results22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical Aβ associated with entorhinal cortex tau while CSF tau/Aβ ratio correlated strongly with cortical tau but not Aβ.
conclusionThe negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker- the CSF total tau/Aβ ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.